Stock Analysis
Axsome Therapeutics, IncAXSM
Sector: Healthcare · Industry: Pharmaceutical Preparations
AnalystsStrong Buy28 analystsPrice is 23% of the way from the year's low to its high.
Cash covers 274% of debt · FY 2025.
PMP Verdict
Weak fundamentals
Strengths
- Financial Health68
Risks
- Growth0
- Profitability0
Weak fundamentals — valuation is the only support.
Market context
-2.9% today· Z 0.8σ
Bull Case
- ✓Altman Z 5.6 — safe-zone balance sheet
What's happening with AXSM
Profile
growth, profitability, moat, earnings quality and valuation lag behind.
How is each axis scored?
- Valuation25/100 · Weak
- P/E vs own history (n/a)10/25
- FCF yield (-0.9%)0/25
- P/S (10.6x)5/25
- EV/EBIT (n/a)10/25
- Growth0/100 · Weak
- Revenue CAGR (n/a)0/25
- Net income CAGR (n/a)0/25
- EPS CAGR 5Y (n/a)0/25
- Fwd implied growth (n/a)0/25
- Profitability0/100 · Weak
- ROIC (n/a)0/25
- ROE (-217.0%)0/25
- Net margin (-24.7%)0/25
- Operating margin (-24.0%)0/25
- Financial Health68/100 · Moderate
- Altman Z (5.64)25/25
- Current ratio (1.55)18/25
- Interest coverage (-27.0x)0/25
- Net cash / debt (Net cash)25/25
- Quality21/100 · Weak
- Piotroski F (5/9)15/25
- Beneish M (-1.66)6/25
- FCF conversion (n/a)0/25
- Margin stability (σ 80.5%)0/25
- Moat0/100 · Weak
- ROIC >12% years (n/a)0/25
- Median gross margin (-49.4%)0/25
- FCF-positive years (0/10 yrs)0/25
- Worst-year net margin (worst -374.0%)0/25
Risk Flags
- ⚠Beneish M -1.66 — earnings-manipulation flag
- ⚠Negative FCF margin (-0.1%) — burning cash
- ⚠SBC 12.4% of revenue — real dilution cost
- ⚠10 loss-making years in recent history
- ⚠Interest coverage -27.0× — thin debt cushion
About Axsome Therapeutics, Inc
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. Show more
It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
Headquarters: NEW YORK, NY · Employees: 925 · Website ↗
Price History
Weekly Candlestick Chart — up to 5Y
Key Metrics
Financial snapshot · Tap any metric for its definition and grade
TTM Snapshot
trailing twelve months · YoYValuation
25EP/E (TTM)—
Price / TTM EPS (own statements)
P/FCF—
Price / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield-0.9%D
Grade D: NegativeTTM (OCF − CapEx) / Market Cap — vs own 5Y history: -13.5%–-0.5% · 89th pct
P/S (TTM)10.60xD
Grade D: ExpensivePrice / TTM Revenue (own statements) — vs own 5Y history: 2.1x–78.6x · 27th pct
EV/EBITDA—
Enterprise value / EBITDA (Finnhub) — capital-structure neutral
EV/Sales10.9xD
Grade D: Very expensiveEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E63.0xD
Grade D: ExpensivePrice / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B Ratio93.21xD
Grade D: Very expensivePrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio1.42B
Grade B: FairFinnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield—
TTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio—
Dividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
0EROIC—
NOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROE-217.0%D
Grade D: WeakReturn on Equity. Neg. equity = heavy buybacks
ROA-27.1%D
Grade D: WeakReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin-24.7%D
Grade D: LowNet Income / Revenue
Operating Margin-24.0%D
Grade D: LowTTM EBIT / TTM Revenue
Gross Margin-24.0%D
Grade D: LowGross Profit / Revenue
FCF Margin-9.3%D
Grade D: LowFCF / Revenue
True FCF Margin-21.7%D
Grade D: LowTTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Growth
0ERevenue CAGR—
Compound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR—
Compound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)—
Compound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth—
Analyst forward EPS (normalized basis) vs our GAAP TTM EPS — different bases, so extreme values usually mark cyclically depressed TTM earnings, not real growth
Dilution (5Y)—
Share count change over 5Y
SBC / Net Income—
Stock-based comp/Net income. >30% = dilution risk
SBC / Revenue12.4%D
Grade D: HighTTM stock-based comp / TTM Revenue
Financial Health
68BAltman Z-Score5.64A
Grade A: SafeBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio1.55xC
Grade C: OkCurrent Assets/Liabilities
Quick Ratio1.30xA
Grade A: High(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage-27.0xD
Grade D: RiskyEBIT/Interest. >10 Strong
Debt RepaymentNet CashA
Grade A: FastYears to repay net debt via FCF
Net Debt/EBIT1.1xA
Grade A: LowLeverage. <2x Low, >4x High
Debt/Equity1.33xC
Grade C: MedDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt2.74xA
Grade A: CoveredCash covers how much of total debt. >1 = could repay all debt from cash
Quality
21EPiotroski F-Score5/9C
Grade C: AverageFinancial strength 0–9. >7 Strong
Beneish M-Score-1.66D
Grade D: RiskyEarnings manipulation risk. < -2.22 Safe
FCF Conversion—
FCF / Net Income
Margin Stability80.5%D
Grade D: VolatileEBIT margin std deviation. Lower = stable
Capex / Revenue0.1%A
Grade A: Asset-lightTTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover1.10xA
Grade A: HighRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
Insider Transactions
SEC Form 4 · 8 recordsP/S codes are the directional signal; grants, option exercises and tax withholding carry none. Form 4 doesn't flag 10b5-1 plans — scheduled sales may appear within open-market sells.
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Jacobson Mark L. Filed | Jacobson Mark L. | Option exercise | -10000 | |
Jacobson Mark L. Filed | Jacobson Mark L. | SellOpen market sale | -10000 | |
Jacobson Mark L. Filed | Jacobson Mark L. | Option exercise | +10.0K | |
TABUTEAU HERRIOT Filed | TABUTEAU HERRIOT | Option exercise | -4660 | |
TABUTEAU HERRIOT Filed | TABUTEAU HERRIOT | SellOpen market sale | -4660 |
Show 3 more filingsShow fewer filings
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
TABUTEAU HERRIOT Filed | TABUTEAU HERRIOT | Option exercise | +4.7K | |
TABUTEAU HERRIOT Filed | TABUTEAU HERRIOT | Option exercise | -45004 | |
TABUTEAU HERRIOT Filed | TABUTEAU HERRIOT | SellOpen market sale | -45004 |
Option exercise (M) rows report a derivative leg, not an open-market sale — a paired negative entry is the option position being consumed.
More metrics — Moat, Per Share, Balance Sheet, MarketHide additional metrics
Moat
0EROIC >12% Years—
Share of completed fiscal years with ROIC > 12% — measures multi-year capital-return durability
Gross Margin (Med.)-49.4%D
Grade D: WeakMedian annual gross margin across available fiscal years — pricing-power durability
FCF-Positive Years0/10 yrsD
Grade D: WeakShare of completed fiscal years with positive free cash flow
Net Margin Floor-374.0%D
Grade D: WeakWeakest annual net margin across completed fiscal years — recession/downcycle resilience
Per Share
EPS (TTM)—
TTM net income per share (Finnhub fallback)
Cash / Share$6.12
Cash & short-term investments per share (Finnhub)
Book Value / Share$1.59
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt$117.75M
Total debt obligations (short + long term)
Cash & Equiv.$322.93M
Cash and short-term investments
Net Debt$-205.19MA
Grade A: Net CashTotal Debt minus Cash. Negative = Net Cash position
Total Equity$88.30M
Shareholders' equity (book value)
Asset / Liability1.15xC
Grade C: AdequateTotal Assets / Total Liabilities
Market
Market Cap$8.23B
Current Market Capitalization
Beta0.80B
Grade B: MarketPrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Jun 2026 · Ratio snapshot Oct 17, 2026
Key Insights: Axsome Therapeutics, Inc (AXSM)
AXSM is down 2.87% at the last close. Piotroski F-Score of 5/9 indicates mixed fundamentals for Axsome Therapeutics, Inc. Altman Z-Score of 5.64 sits comfortably in the safe zone (≥ 2.99), indicating low bankruptcy risk. Beneish M-Score of -1.66 is above the −1.78 flag threshold, a signal that reported earnings warrant closer scrutiny. Free-cash-flow margin is negative (-9%) — the business currently burns cash.
- Company is effectively debt-free after netting cash.
- Interest coverage of -27.0× leaves little room for earnings shocks.
- Axsome Therapeutics, Inc posted a net loss in 10 of 10 available completed fiscal years (2016–2025).
- At a valuation score of 25/100, AXSM trades at a premium to its historical multiples.
See how AXSM ranks on the Capex Tracker — top 50 capital spenders compared.
Recent Market Moves
See all AXSM moves →| Date | Session | Price | Move | Z-Score |
|---|---|---|---|---|
| Oct 14 | Regular | 162.77 | +4.12% | 3.28 |
| Oct 14 | After-hours | 162.22 | +3.77% | 3.09 |
| Oct 13 | Regular | 157.19 | -5.31% | -2.42 |
| Oct 13 | After-hours | 156.35 | -5.81% | -2.71 |
Frequently Asked Questions about AXSM
What is the current Axsome Therapeutics, Inc (AXSM) stock price?
AXSM is trading at $157.14 at the last market close, down 2.87% on the session. PreMarketPrice tracks AXSM pre-market, intraday and after-hours prices.
Is AXSM stock a buy right now?
PreMarketPrice's quantitative model rates Axsome Therapeutics, Inc's financial health at 68/100. This is a data-driven snapshot of fundamentals, not investment advice.
Is AXSM stock overvalued?
Axsome Therapeutics, Inc trades at a trailing P/E of n/a and our valuation score rates it 25/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does Axsome Therapeutics, Inc report earnings?
No confirmed earnings date is currently scheduled for AXSM. The Earnings section lists recent reports and updates as dates are announced.
What sector does Axsome Therapeutics, Inc operate in?
Axsome Therapeutics, Inc operates in the Healthcare sector, within the Pharmaceutical Preparations industry. The Related Stocks section lists sector peers for comparison.
What does Axsome Therapeutics, Inc do?
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company.
About Axsome Therapeutics, Inc (AXSM) Stock
Axsome Therapeutics, Inc (AXSM) is a US-listed stock operating in the Healthcare sector, specifically the Pharmaceutical Preparations industry. As of the latest update, Axsome Therapeutics, Inc is trading at $157.14, down 2.87% on the day with a market capitalization of $8.2 billion. The financial health score for AXSM is 68/100, which indicates good financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for AXSM stock.
AXSM Stock Analysis & Key Metrics
On PreMarketPrice, you can track Axsome Therapeutics, Inc (AXSM) across multiple dimensions:
- Pre-market price & movement: Real-time AXSM stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for AXSM with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for Axsome Therapeutics, Inc across multiple reporting periods.
- Financial health score: A composite score of 68/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for AXSM.
- Sector peers: Compare AXSM against 6 other healthcare stocks on key financial metrics.
Is AXSM a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate Axsome Therapeutics, Inc (AXSM) as an investment. The financial health score of 68/100 suggests good financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.Axsome Therapeutics, Inc (AXSM) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.